Zhong Alex, Choudhary Pratik, McMahon Chantal, Agrawal Pratik, Welsh John B, Cordero Toni L, Kaufman Francine R
1 Medtronic , Northridge, California.
2 Diabetes Research Group, King's College London , London, United Kingdom .
Diabetes Technol Ther. 2016 Oct;18(10):657-663. doi: 10.1089/dia.2016.0216. Epub 2016 Sep 27.
Automated insulin management features of the MiniMed 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery upon SG recovery. The effectiveness of these features was evaluated using CareLink software data.
Anonymized data from MiniMed 640G system users (n = 4818), MiniMed 530G system users (n = 39,219), and MiniMed Paradigm Veo™ system users (n = 43,193) who voluntarily uploaded pump and sensor data were retrospectively analyzed. Comparisons were made between days in which system features were enabled at any time and those in which they were not. Comparisons were also made between pump suspension events for which insulin delivery was automatically or manually resumed and between glycemic parameters of users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system.
Days in which the MiniMed 640G "suspend before low" feature was enabled had lower percentages of SG readings ≤70 mg/dL (3.9 mmol/L) or ≥240 mg/dL (13.3 mmol/L) than days when it was not enabled (P < 0.001 for each). Users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system had fewer excursions below ≤70 mg/dL (P < 0.001) and ≥240 mg/dL (P < 0.001). SG values following automatically resumed pump suspension events recovered more rapidly and had a more stabilized endpoint than following manually resumed events.
Automated insulin management features of the MiniMed 640G system can reduce the frequency of both high and low SG values and help stabilize SG after resumption of insulin delivery.
美敦力640G传感器增强型胰岛素泵系统的自动胰岛素管理功能包括,根据预测的低传感器葡萄糖(SG)值进行暂停(“在低血糖前暂停”)、根据现有的低SG值进行暂停(“低血糖时暂停”),以及在SG值恢复后自动重启基础胰岛素输注。使用CareLink软件数据对这些功能的有效性进行了评估。
对自愿上传胰岛素泵和传感器数据的美敦力640G系统用户(n = 4818)、美敦力530G系统用户(n = 39219)和美敦力Paradigm Veo™系统用户(n = 43193)的匿名数据进行回顾性分析。对系统功能在任何时间启用的天数与未启用的天数进行比较。还对胰岛素输注自动或手动恢复的泵暂停事件之间,以及从美敦力Paradigm Veo系统切换到美敦力640G系统的用户的血糖参数进行了比较。
启用美敦力640G“在低血糖前暂停”功能的日子里,SG读数≤70mg/dL(3.9mmol/L)或≥240mg/dL(13.3mmol/L)的百分比低于未启用该功能的日子(每项P < 0.001)。从美敦力Paradigm Veo系统切换到美敦力640G系统的用户,血糖低于≤70mg/dL(P < 0.001)和≥240mg/dL(P < 0.001)的波动较少。与手动恢复的事件相比,胰岛素泵暂停事件自动恢复后,SG值恢复得更快,终点更稳定。
美敦力640G系统的自动胰岛素管理功能可以降低高SG值和低SG值的发生频率,并有助于在恢复胰岛素输注后稳定SG值。